Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder.
ibogaine
ketamine
opioid use disorder
psychedelic agents
psychoplastogens
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
05
2023
accepted:
09
08
2023
medline:
7
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
epublish
Résumé
The United States is entering its fourth decade of the opioid epidemic with no clear end in sight. At the center of the epidemic is an increase in opioid use disorder (OUD), a complex condition encompassing physical addiction, psychological comorbidities, and socioeconomic and legal travails associated with the misuse and abuse of opioids. Existing behavioral and medication-assisted therapies show limited efficacy as they are hampered by lack of access, strict regimens, and failure to fully address the non-pharmacological aspects of the disease. A growing body of research has indicated the potential of hallucinogens to efficaciously and expeditiously treat addictions, including OUD, by a novel combination of pharmacology, neuroplasticity, and psychological mechanisms. Nonetheless, research into these compounds has been hindered due to legal, social, and safety concerns. This review will examine the preclinical and clinical evidence that psychoplastogens, such as ibogaine, ketamine, and classic psychedelics, may offer a unique, holistic alternative for the treatment of OUD while acknowledging that further research is needed to establish long-term efficacy along with proper safety and ethical guidelines.
Identifiants
pubmed: 37675046
doi: 10.3389/fphar.2023.1221719
pii: 1221719
pmc: PMC10477608
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1221719Informations de copyright
Copyright © 2023 Hornick and Stefanski.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Alkaloids Chem Biol. 2001;56:249-81
pubmed: 11705112
ACS Pharmacol Transl Sci. 2020 Dec 10;4(2):568-572
pubmed: 33861219
J Psychopharmacol. 2017 May;31(5):606-613
pubmed: 28196428
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1019-1022
pubmed: 34139922
Addiction. 2000 Apr;95(4):575-90
pubmed: 10829333
CNS Neurosci Ther. 2013 Jun;19(6):370-80
pubmed: 23575437
Drugs R D. 2015 Mar;15(1):37-43
pubmed: 25773961
Cell Rep. 2018 Jun 12;23(11):3170-3182
pubmed: 29898390
J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265
pubmed: 29608409
Am J Drug Alcohol Abuse. 2018;44(1):37-46
pubmed: 28402682
Curr Neuropharmacol. 2014 Sep;12(5):444-61
pubmed: 25426012
J Affect Disord. 2014 Mar;156:24-35
pubmed: 24388038
Clin Pharmacol Ther. 2022 Apr;111(4):886-895
pubmed: 34743319
Lancet. 1970 Jun 27;1(7661):1370-1
pubmed: 4194126
J Psychoactive Drugs. 2016 Jul-Aug;48(3):214-7
pubmed: 27192438
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
JAMA Psychiatry. 2017 Apr 01;74(4):399-405
pubmed: 28249076
Anesth Analg. 2005 Aug;101(2):407-411
pubmed: 16037153
Acta Psychiatr Scand. 2016 Jul;134(1):48-56
pubmed: 27028832
J Clin Pharm Ther. 2017 Apr;42(2):147-154
pubmed: 28111761
J Neurosci. 2005 Jan 19;25(3):619-28
pubmed: 15659598
Ther Adv Psychopharmacol. 2016 Jun;6(3):193-213
pubmed: 27354908
Front Neurosci. 2023 Apr 17;17:1156319
pubmed: 37139521
Am J Addict. 1999 Summer;8(3):234-42
pubmed: 10506904
J Nerv Ment Dis. 1996 Feb;184(2):86-94
pubmed: 8596116
Neuron. 2021 Aug 18;109(16):2535-2544.e4
pubmed: 34228959
Mol Psychiatry. 2021 Nov;26(11):6104-6106
pubmed: 34006965
Reg Anesth Pain Med. 2018 Jul;43(5):456-466
pubmed: 29870457
J Psychopharmacol. 2021 Apr;35(4):375-383
pubmed: 33601929
N Engl J Med. 2022 Nov 3;387(18):1637-1648
pubmed: 36322843
J Subst Abuse Treat. 2015 May;52:48-57
pubmed: 25601365
Biol Psychiatry. 2014 Jul 1;76(1):40-6
pubmed: 24035344
J Psychoactive Drugs. 2007 Mar;39(1):13-9
pubmed: 17523581
Arch Gen Psychiatry. 1973 Jun;28(6):808-14
pubmed: 4575166
Nat Rev Neurosci. 2011 Oct 20;12(11):652-69
pubmed: 22011681
Neuropsychopharmacology. 2022 Sep;47(10):1854-1862
pubmed: 35660802
J Affect Disord. 2023 Mar 15;325:127-134
pubmed: 36623562
Anesth Analg. 1998 Nov;87(5):1186-93
pubmed: 9806706
Nature. 1994 Feb 17;367(6464):607-14
pubmed: 7509043
Molecules. 2015 Jan 29;20(2):2208-28
pubmed: 25642835
Int Pharmacopsychiatry. 1971;6(4):223-35
pubmed: 4950565
Drug Alcohol Depend. 2022 Apr 1;233:109356
pubmed: 35286849
Biol Psychiatry. 2023 Feb 1;93(3):215-223
pubmed: 36266118
Pharmacol Rev. 2018 Jul;70(3):621-660
pubmed: 29945898
Ann Emerg Med. 2020 Dec;76(6):782-787
pubmed: 32782084
Addiction. 2016 Apr;111(4):695-705
pubmed: 26599131
Science. 2010 Aug 20;329(5994):959-64
pubmed: 20724638
J Psychopharmacol. 2012 Jul;26(7):994-1002
pubmed: 22406913
Curr Neuropharmacol. 2019;17(2):108-128
pubmed: 29366418
Neurosci Biobehav Rev. 2022 Sep;140:104793
pubmed: 35878791
JAMA Psychiatry. 2022 Oct 1;79(10):953-962
pubmed: 36001306
J Am Acad Psychiatry Law. 2023 Jun;51(2):160-166
pubmed: 37311597
Front Pharmacol. 2013 Dec 27;4:161
pubmed: 24409146
Nature. 2021 Jan;589(7842):474-479
pubmed: 33299186
Eur J Pharmacol. 2019 Oct 5;860:172547
pubmed: 31348905
Ann N Y Acad Sci. 2000 Sep;914:394-401
pubmed: 11085338
Curr Drug Abuse Rev. 2013 Mar;6(1):3-16
pubmed: 23627782
J Psychoactive Drugs. 2018 Sep-Oct;50(4):287-297
pubmed: 30020025
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003409
pubmed: 16034898
J Subst Abuse Treat. 2002 Dec;23(4):273-83
pubmed: 12495789
J Neurosci. 2014 Jun 4;34(23):7899-909
pubmed: 24899712
Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60
pubmed: 27441452
Nature. 2011 Jun 15;475(7354):91-5
pubmed: 21677641
Am J Drug Alcohol Abuse. 2018;44(1):24-36
pubmed: 28541119
Reg Anesth Pain Med. 2018 Jul;43(5):521-546
pubmed: 29870458
Science. 2023 Feb 17;379(6633):700-706
pubmed: 36795823
J Affect Disord. 2023 Apr 14;327:120-127
pubmed: 36740140
Sci Rep. 2022 Apr 7;12(1):4099
pubmed: 35393455
Neuropsychopharmacology. 2022 Jul;47(8):1574-1581
pubmed: 35046508
Cells. 2023 Mar 22;12(6):
pubmed: 36980303
Biochemistry. 2022 Feb 1;61(3):127-136
pubmed: 35060714
Eur J Neurosci. 2021 Jan;53(1):126-139
pubmed: 31811669
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Addiction. 2022 Jan;117(1):118-128
pubmed: 33620733
Psychopharmacology (Berl). 2021 Jul;238(7):1899-1910
pubmed: 33694031
Int J Drug Policy. 2019 Apr;66:80-81
pubmed: 30743091
Addiction. 2012 Jan;107(1):27-38
pubmed: 21777321
JAMA Psychiatry. 2022 Sep 1;79(9):932-934
pubmed: 35830198
Front Psychiatry. 2020 Jan 22;10:955
pubmed: 32038317
Trends Pharmacol Sci. 2021 Nov;42(11):929-942
pubmed: 34565579
J Psychoactive Drugs. 2019 Apr-Jun;51(2):155-165
pubmed: 30967101
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46
pubmed: 22065255
Brain Res. 2014 May 8;1562:69-75
pubmed: 24675031
J Psychopharmacol. 2018 Dec;32(12):1385-1391
pubmed: 30255717
Ther Adv Psychopharmacol. 2021 Jan 25;11:2045125320986634
pubmed: 33717431
J Psychoactive Drugs. 1997 Apr-Jun;29(2):165-83
pubmed: 9250944
Int J Drug Policy. 2022 Feb;100:103518
pubmed: 34758431
Mol Psychiatry. 2020 Nov;25(11):2742-2758
pubmed: 32086434